# Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

> **NCT02446223** · PHASE4 · COMPLETED · sponsor: **Goldman, Butterwick, Fitzpatrick and Groff** · enrollment: 21 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Inggenol Mebutate 0.015%

## Key facts

- **NCT ID:** NCT02446223
- **Lead sponsor:** Goldman, Butterwick, Fitzpatrick and Groff
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446223, "Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02446223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*